Researchers at UCLA’s Jonsson Comprehensive Cancer Center discovered that treating women with HER2-positive metastatic breast cancer with trastuzumab deruxtecan (T-DXd) significantly prolongs disease control and cancer growth compared to current standard of care, trastuzumab emtansine(T-DM1).
T-Dxd is a HER2-targeted monoclonal antibody that delivers high doses of chemotherapy directly to cancer cells that express HER2.
Compared to T-DM1, the medication improved progression-freesurvival by 72%.
At 12 months, 76 percent of patients treated with T-DXd had not progressed, meaning their disease remained under control. By 12 months,only 34% of T-DM1 patients had not progressed.